Positive Niemann-Pick disease type C (NPC) and GM2 gangliosidosis data from nizubaglustat Phase 2 RAINBOW study conducted by Azafaros presented at major metabolic disease conference
10.9.2024 10:00:00 EEST | Business Wire | Press release
Azafaros has announced that data from the ongoing double-blind, placebo-controlled Phase 2 RAINBOW study investigating its lead asset, nizubaglustat in patients with Niemann-Pick disease type C (NPC) or GM2 gangliosidosis, were presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal.
The results of part one of the study, designed to determine the safety, pharmacodynamics, and pharmacokinetics of the Company’s lead asset nizubaglustat, demonstrated the compound had a positive safety profile and was well-tolerated in the 13 participants in the study.
All patients are now enrolled in the extension phase of the trial, where initial unblinded data on 10 patients showed 8 had improved or stabilized SARA (Scale for the Assessment and Rating of Ataxia) scores. Additionally, a reduction in seizure frequency was observed for the participants who had experienced daily seizures before recruitment into the study.
Data from the RAINBOW study will be used to inform the target dose for Azafaros’ planned Phase 3 pivotal studies, due to be initiated 2025.
At the conference, Azafaros also presented 12-month follow-up data from the company’s PRONTO trial, a natural history study of late-infantile/juvenile GM1 and GM2 gangliosidoses.
PRONTO is the largest prospective natural history study of these two rare diseases, providing valuable insights for the further development of nizubaglustat in GM1 and GM2 and for the gangliosidoses research community in general.
Stefano Portolano, MD, CEO of Azafaros, said: “The RAINBOW trial results support the positive safety profile of nizubaglustat and provide us with encouraging early efficacy trends for the compound. We greatly appreciate the opportunity to discuss these data with the scientific community at the SSIEM annual symposium, and believe our compound offers a potential new solution to patients with rare lysosomal storage disorders with neurological involvement where there is a strong unmet medical need. We look forward to using the insights provided by results from both RAINBOW and PRONTO to keep the strong momentum of our clinical program and move the compound into pivotal trials next year.”
Azafaros is thankful to the patients and their families for their participation in the RAINBOW study.
Ends
About the RAINBOW study
The RAINBOW trial is a Phase 2 clinical study designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of AZ-3102 (nizubaglustat) in patients with GM2 and Niemann-Pick type C (NPC) diseases. The study was conducted across three sites in Brazil, involving 13 patients older than 12 years of age. In the first part of the study patients were randomized to receive either a high dose or low dose of nizubaglustat or placebo. All patients continued into the second part of the study where they are randomized to receive either high or low dose nizubaglustat for 52 weeks.
About the PRONTO study
The PRONTO study is a prospective natural history study designed to assess the progression of neurological disease in late-infantile and juvenile GM1 and GM2 gangliosidoses. The study includes participants with a late-infantile/juvenile form, genetic diagnosis, and who are between 2 and 20 years old and the main objective was to provide insight and understanding of disease progression using clinical scales, caregiver questionnaires, and actigraphy. A total of 30 participants were recruited from 6 countries with at least 12-month follow-up data on 21 participants.
About nizubaglustat
Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC).
Nizubaglustat has received the following designations and support:
United States Food and Drug Administration (FDA)
Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC.
Orphan Drug Designations (ODD) for GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC.
IND Clearance and Fast Track Designation for GM1/GM2 gangliosidoses and NPC
European Medicines Agency (EMA)
Orphan Medicinal Product Designation (OMPD) for the treatment of GM2 gangliosidosis.
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Innovation Passport for the treatment of GM1 and GM2 gangliosidoses.
About GM1 and GM2 Gangliosidoses
GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS), resulting in progressive and severe neurological impairment and early death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available.
About Niemann-Pick Disease Type C (NPC)
Niemann-Pick disease type C (NPC) is a progressive, life-limiting neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood.
About Azafaros
Azafaros is a clinical-stage company founded in 2018 by scientists with a deep understanding of rare genetic disease mechanisms, using discoveries made by scientists at Leiden University and Amsterdam UMC. Azafaros is led by a team of highly experienced industry experts and aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. The Azafaros team is dedicated to rapidly bring new drugs to the rare disease patients who need them. The company is supported by a syndicate of leading investors including Forbion, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910536439/en/
Contacts
Azafaros B.V.
Email: info@azafaros.com
www.azafaros.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.azafaros.co
m&esheet=54118405&newsitemid=20240910536439&lan=en-US&anchor=www.azafaros.com&in
dex=7&md5=7cdd87b3a6b217d5680187b41bdecb58
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release
TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (
Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 17:40:00 EET | Press release
Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that coordinated, network-level defenses are reducing the impact of these threats. “AI is changing the economics of fraud
Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 17:00:00 EET | Press release
Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro brings decades of experience in the supercomputing industry. During his 16-year tenure as President and CEO of Cray, he led the company through
SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 16:30:00 EET | Press release
SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial networks. As demand grows for ubiquitous and resilient connectivity, Direct-to-Device services are expected to become an important c
From returns to restaurant bookings: Klarna’s AI assistant finds the best product & price, buys it for you, and you don’t pay until it arrives17.11.2026 16:26:00 EET | Press release
Klarna, the everyday finance network, today announced the Klarna AI-assistant, a personal assistant that handles shopping, returns, bookings, and everyday admin, so you don’t have to. Currently live with a small group of early users, the AI-assistant acts like a personal concierge, handling tasks on each customer’s behalf while keeping them firmly in control. Waitlist opens this week. The Klarna AI-assistant finds options and helps people decide, books anything from a table for two, to a babysitter, and keeps track of what they’re waiting for. It drafts email replies for approval, files receipts, and flags upcoming birthdays with gift ideas. This new AI-assistant builds on Klarna’s shopping assistant, a popular feature in its app. Klarna customers have spent more than $34 billion through the app’s built-in browser since 2020, a feature that lets you shop any website, including stores that don’t offer Klarna. “Back in 2015, we thought about the future of finance and imagined a day when
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom